Details of the Drug Formulation (DFM)
| General Information of DFM (ID: F24371) | |||||
|---|---|---|---|---|---|
| Name |
Larotrectinib 25 mg capsule
|
||||
| Company |
Bayer Healthcare Pharmaceuticals ; Loxo Oncology
|
||||
| Active Pharmaceutical Ingredient (API) | Larotrectinib |
API Info
 click to show the detail info of this API
|
|||
| Approved | |||||
| Drug Inactive Ingredient (DIGs) | |||||
| DIG ID | DIG Info | DIG Name | DIG Functional Class | ||
| E00FTX | DIG Info | Gelatin | Other agent | ||
| E05BSD | DIG Info | Titanium dioxide | Coating agent ... | ||
| Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM | ||||||
|---|---|---|---|---|---|---|
| Oxidoreductase (ORase) | ||||||
| DBT Name: Cytochrome P450 2E1 (CYP2E1) | Click to Show/Hide | |||||
| Detailed Information |
DBT Info
click to show the detail info of this DBT
|
|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Gelatin | |||||
| Biological Activity | IC50 = 141.2 uM (tested by experiment) | [1] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | CP2E1_HUMAN | |||||
| DBT Name: Cytochrome P450 2C9 (CYP2C9) | Click to Show/Hide | |||||
| Detailed Information |
DBT Info
click to show the detail info of this DBT
|
|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Gelatin | |||||
| Biological Activity | EC50 = 249.5 uM (tested by experiment) | [1] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | CP2C9_HUMAN | |||||
| DBT Name: Mephenytoin 4-hydroxylase (CYP2C19) | Click to Show/Hide | |||||
| Detailed Information |
DBT Info
click to show the detail info of this DBT
|
|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Gelatin | |||||
| Biological Activity | EC50 = 20.5 uM (tested by experiment) | [1] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | CP2CJ_HUMAN | |||||
| DBT Name: Debrisoquine 4-hydroxylase (CYP2D6) | Click to Show/Hide | |||||
| Detailed Information |
DBT Info
click to show the detail info of this DBT
|
|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Gelatin | |||||
| Biological Activity | EC50 = 379.9 uM (tested by experiment) | [1] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | CP2D6_HUMAN | |||||
| Lyase/isomerase/ligase (L/I/G) | ||||||
| DBT Name: Cholesterol 25-hydroxylase (CYP1A2) | Click to Show/Hide | |||||
| Detailed Information |
DBT Info
click to show the detail info of this DBT
|
|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Gelatin | |||||
| Biological Activity | IC50 = 40.9 uM (tested by experiment) | [1] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | CP1A2_HUMAN | |||||
| References | |||||
|---|---|---|---|---|---|
| 1 | Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.